Heart and Vascular
POTS
Postural Orthostatic Tachycardia Syndrome (POTS)
A Phase 2 Double-Blind Placebo-Controlled Single-Dose Study of Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of REGN7544, an NPR1 Antagonist Monoclonal Antibody, in Patients with Postural Orthostatic Tachycardia Syndrome
Contact Research Team:
[email protected]
Site principal investigator:
John Lee, MD
Learn more about this study:
NCT06593600